Plain-English translation of NCT06388707 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing a new treatment called low-intensity focused ultrasound neuromodulation for people with drug-resistant temporal lobe epilepsy. The treatment uses focused sound waves directed at specific brain regions to calm overactive nerve activity and reduce seizures. Researchers want to see if this treatment is safe and whether it can help decrease how often seizures happen.
Many people with temporal lobe epilepsy don't get relief from standard anti-seizure medications, and surgery isn't an option for everyone. This trial explores whether focused ultrasound could offer a new way to control seizures without surgery or additional drugs.
You likely qualify if…
You likely don't qualify if…
You would first complete an 8-week observation period where you keep a detailed seizure diary while staying on your current medications. Then you would receive 6 focused ultrasound treatments over 3 consecutive weeks at a research clinic. After treatment ends, you'll continue tracking your seizures and return for follow-up visits for 12 weeks. Throughout the entire study, you'll continue taking your regular anti-seizure medications as prescribed.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
United States